Study of WVE-003 in Patients With Huntington's Disease

NCT05032196 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

47

Enrollment

INDUSTRY

Sponsor class

Conditions

Huntington Disease

Interventions

DRUG: SAD: 30mg WVE-003
DRUG: SAD: 60mg WVE-003
DRUG: SAD: 90mg WVE-003
DRUG: SAD: Pooled Placebo
DRUG: MD: 30mg WVE-003
DRUG: MD: Placebo

Sponsor

Wave Life Sciences Ltd.